KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Receivables (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Receivables for 16 consecutive years, with $441.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 34.23% to $441.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $441.3 million, a 34.23% increase, with the full-year FY2025 number at $441.3 million, up 34.23% from a year prior.
  • Receivables was $441.3 million for Q4 2025 at Halozyme Therapeutics, up from $346.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $441.3 million in Q4 2025 to a low of $91.0 million in Q4 2021.
  • A 5-year average of $233.7 million and a median of $229.1 million in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 309.6% in 2021, then decreased 27.49% in 2023.
  • Halozyme Therapeutics' Receivables stood at $91.0 million in 2021, then surged by 154.0% to $231.1 million in 2022, then grew by 1.38% to $234.3 million in 2023, then skyrocketed by 40.34% to $328.8 million in 2024, then skyrocketed by 34.23% to $441.3 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Receivables are $441.3 million (Q4 2025), $346.0 million (Q3 2025), and $315.1 million (Q2 2025).